Larson Financial Group LLC acquired a new stake in Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) in the 4th quarter, HoldingsChannel reports. The fund acquired 8,162 shares of the company’s stock, valued at approximately $116,000.
Several other hedge funds and other institutional investors have also made changes to their positions in TAK. XY Capital Ltd lifted its stake in Takeda Pharmaceutical by 432.5% in the fourth quarter. XY Capital Ltd now owns 765,137 shares of the company’s stock worth $10,919,000 after acquiring an additional 621,440 shares during the last quarter. FMR LLC lifted its stake in Takeda Pharmaceutical by 4.7% in the third quarter. FMR LLC now owns 2,593,350 shares of the company’s stock worth $40,119,000 after acquiring an additional 115,947 shares during the last quarter. Brandes Investment Partners LP lifted its stake in Takeda Pharmaceutical by 2.1% in the third quarter. Brandes Investment Partners LP now owns 1,802,036 shares of the company’s stock worth $27,877,000 after acquiring an additional 36,717 shares during the last quarter. Citigroup Inc. lifted its stake in Takeda Pharmaceutical by 5.6% in the third quarter. Citigroup Inc. now owns 57,941 shares of the company’s stock worth $896,000 after acquiring an additional 3,089 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in shares of Takeda Pharmaceutical during the 3rd quarter worth approximately $2,105,000. Hedge funds and other institutional investors own 9.17% of the company’s stock.
Takeda Pharmaceutical Stock Down 1.2 %
Shares of NYSE:TAK opened at $13.07 on Friday. The company has a market capitalization of $41.35 billion, a PE ratio of 19.80, a P/E/G ratio of 3.02 and a beta of 0.53. The company has a current ratio of 1.06, a quick ratio of 0.55 and a debt-to-equity ratio of 0.64. Takeda Pharmaceutical Company Limited has a twelve month low of $13.05 and a twelve month high of $17.11. The firm has a 50 day simple moving average of $14.09 and a 200-day simple moving average of $14.21.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Recommended Stories
- Five stocks we like better than Takeda Pharmaceutical
- Find and Profitably Trade Stocks at 52-Week Lows
- Semiconductor Shakeout: Finding Potential Amidst Turmoil
- What is a Low P/E Ratio and What Does it Tell Investors?
- Hasbro’s Management Made All the Right Calls This Quarter
- What Are Dividends? Buy the Best Dividend Stocks
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report).
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.